Artificial Intelligence (AI) has been a game-changer in many sectors, including healthcare. AI has been successful in Assistive Technology, an area that’s always been at the forefront of technology.
AI has the potential to revolutionize AT, as highlighted by the UN Special Rapporteur on the rights of persons with disabilities. It can enhance assistive robots, autonomous wheelchairs, and guidance systems for visually impaired individuals. Speech recognition improvements are improving AT applications, while smart homes can boost independence and well-being.
However, challenges exist. AI systems learn from data “training sets,” and if these sets lack diversity, the technology may not reflect the needs of diverse human experiences. Also, the transparency of the data labelling process and lack of diversity in data collection can lead to biased AI tools. Therefore, AI training sets must include AT users to ensure the technology caters to their needs.
Many of these technologies are still in development and have yet to overcome significant barriers. For example, people with dysarthria are hard for speech recognition systems to understand, and smart wheelchairs have trouble detecting descending stairs.
The healthcare workforce should be trained in using digital products and AI tools to educate future generations. This is part of a broader framework to support these technologies’ development and sustainability.
Regulations, standards, and policies also need to keep pace with technological advancements. The proposed EU legislation has raised concerns among the European Disability Forum as it does not sufficiently address and protect the rights of persons with disabilities, especially when AI is used for access to public and private services.
AI could revolutionize AT, but it’s important to involve AT users and healthcare providers in the development process. This involves talking about the ethical use of these technologies and creating rules and policies to govern them.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.